文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

乳香酸治疗放射性脑水肿与脑坏死的系统Meta叙事综述

Boswellia serrata for the Management of Radiation-Induced Cerebral Edema and Necrosis: A Systematic Meta-Narrative Review of Clinical Evidence.
PubMed 文献 · Adv Radiat Oncol · 2025-02-01

本综述综合MEDLINE、Embase、Scopus和Cochrane数据库文献,评估乳香酸(BA)在脑照射期间或之后用于放射性脑水肿和脑坏死(RN)的临床证据。共纳入6条记录、130例患者,约半数患者从BA获益(影像学或临床),约三分之一可成功减量地塞米松或避免长期使用。BA耐受性良好,但最佳剂型、时机和剂量未知,临床证据不足,需精心设计的前瞻性试验进一步研究。

要点

  • 共纳入6条记录、130例患者,约半数从BA获益(影像学或临床)。
  • 约三分之一患者可成功减量地塞米松或避免长期使用。
  • BA耐受性良好,最常见为轻度胃肠道不适;最佳剂型、时机和剂量未知。

核心结论

  • 总体而言,BA用于放射性脑水肿和RN的临床证据不足,需精心设计的前瞻性试验进一步研究这一潜在低成本减少皮质类固醇用量的选择。

研究设计与样本

  • 系统Meta叙事综述,检索MEDLINE、Embase、Scopus和Cochrane数据库,采用Realist and Meta-Narrative Evidence Syntheses: Evolving Standards框架进行Meta叙事汇总。
  • 共纳入6条记录,包括3条关于大照射体积后水肿减轻和3条关于SRS后RN,涵盖130例患者。

主要发现

  • 约半数患者从BA获益(影像学或临床),约三分之一可成功减量地塞米松或避免长期使用。
  • BA耐受性良好,最常报告轻度胃肠道不适。
  • 当前不足包括最佳剂型、时机和剂量未知,每日所需胶囊数量相当大,以及与其他药物相互作用不确定。

关键数值与推荐

  • 纳入标准为报告人类脑照射期间或之后使用BA的文献。

临床怎么用

  • BA作为非处方膳食补充剂,因其抗炎和抗血管生成作用,已被建议作为潜在的减少皮质类固醇用量的替代选择。
  • 对于有症状患者,一线标准治疗包括皮质类固醇,但在免疫治疗时代可能适得其反。

局限性

  • BA用于放射性脑水肿和RN的临床证据不足,需精心设计的前瞻性试验进一步研究。
  • 最佳剂型、时机和剂量未知,每日所需胶囊数量相当大,与其他药物相互作用不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic radiosurgery (SRS) yields excellent local control in patients with a limited number of brain metastases (BMs), but radiation-induced cerebral edema and radiation necrosis (RN) in particular may cause dose-limiting late toxicity, with the same holding true after fractionated radiation therapy for glioma. In symptomatic patients, the first-line standard of care includes corticosteroids, which may, however, be counterproductive in the evolving era of immunotherapy. Boswellic acid (BA), available as an over-the-counter dietary supplement, has been suggested as a potential corticosteroid-sparing alternative because of its anti-inflammatory and antiangiogenic effects. METHODS AND MATERIALS: We performed a comprehensive literature search of the MEDLINE, Embase, Scopus, and Cochrane databases, identifying publications reporting on the use of BA during or after brain irradiation in humans. Using the Realist and Meta-Narrative Evidence Syntheses: Evolving Standards framework, relevant data are summarized using a meta-narrative approach. RESULTS: Six records (3 for edema reduction in large irradiated volumes and 3 for RN after SRS) were identified, encompassing 130 patients. Roughly half of patients benefited from BA (radiographically or clinically) and about one third could successfully taper dexamethasone or prevent its long-term intake. Tolerability of BA was favorable, with mild gastrointestinal discomfort being reported most frequently. Current drawbacks include unknown optimal formulation as well as timing and dosing, a considerably large number of required daily capsules, and uncertain interactions with other drugs. CONCLUSIONS: Overall, the clinical evidence on the use of BA for radiation-induced cerebral edema and RN is lacking and well-designed prospective trials are warranted to further investigate this potential low-cost corticosteroid-sparing option.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Dejonckheere CS, Scafa D, Käsmann L, et al. Boswellia serrata for the Management of Radiation-Induced Cerebral Edema and Necrosis: A Systematic Meta-Narrative Review of Clinical Evidence. Adv Radiat Oncol. 2025. PMID: 40092573. doi:10.1016/j.adro.2025.101732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。